Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.
Geisler CH, Kolstad A, Laurell A, Jerkeman M, Räty R, Andersen NS, Pedersen LB, Eriksson M, Nordström M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group.
Geisler CH, et al. Among authors: jerkeman m.
Br J Haematol. 2012 Aug;158(3):355-62. doi: 10.1111/j.1365-2141.2012.09174.x. Epub 2012 May 29.
Br J Haematol. 2012.
PMID: 22640180
Free article.
Clinical Trial.